Welcome to our dedicated page for Sonoma Pharmaceu SEC filings (Ticker: SNOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations, governance, and financial condition. These SEC filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain audited and unaudited financial statements, revenue by region, gross profit, operating expenses, net loss, and non-GAAP reconciliations such as EBITDA loss. For a company focused on stabilized hypochlorous acid (HOCl) products based on Microcyn technology, these reports help investors understand how sales of wound care, dermatology, eye care, oral and nasal care, podiatry, animal health, and disinfectant products contribute to overall performance.
Current reports on Form 8-K are particularly relevant for tracking material events. Recent 8-K filings describe changes to executive employment agreements, the planned or actual departure of senior officers, an at-the-market issuance sales agreement for common stock, and the filing of updated investor presentations. Other 8-Ks document the results of the annual meeting of stockholders, including director elections, advisory votes on executive compensation, and auditor ratification. These disclosures provide transparency into Sonoma’s governance, compensation practices, and capital-raising activities.
Proxy statements on Schedule 14A offer additional detail on board structure, director and executive biographies, compensation programs, and stockholder proposals. Together with the company’s periodic reports, they allow readers to review how Sonoma aligns management incentives with its strategy of developing and commercializing HOCl-based products.
On this page, users can access Sonoma’s SEC filings as they are made available through EDGAR. AI-powered tools can be used to summarize lengthy documents such as 10-Ks and 10-Qs, highlight key sections on revenue trends, regional performance, operating expenses, and risk factors, and surface information on topics like executive compensation, equity plans, and material agreements disclosed in Forms 8-K and proxy materials.
Form 4 overview – Sonoma Pharmaceuticals (SNOA)
On 19 June 2025 Sonoma Pharmaceuticals filed a Form 4 detailing an equity-compensation grant to Chief Financial Officer Jerome J. Dvonch. The company awarded the executive 13,500 restricted stock units (RSUs), each convertible into one share of common stock at no exercise price. The award vests in full on the third anniversary of the grant date or earlier upon a change of control, aligning long-term incentives with shareholder value.
Following the grant, Mr. Dvonch’s derivative holdings increased to 25,515 RSUs, all held directly. No open-market purchase or sale of common stock occurred, and therefore the transaction has no immediate cash impact on the executive, the company, or existing shareholders; any dilution will materialise only when the RSUs convert to shares. The filing is a routine disclosure required under Section 16(a) and does not signal a material change in Sonoma Pharmaceuticals’ operations, strategy, or near-term financial outlook.